Today: Ngam Advisors L.P. Sold shares of Mednax Inc. (MD)

Today: Ngam Advisors L.P. Sold shares of Mednax Inc. (MD)

Ngam Advisors L.P. decreased its stake in Mednax Inc. (NYSE:MD) by 11.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 175,023 shares of the company’s stock after selling 22,422 shares during the period. Ngam Advisors L.P. owned about 0.19% of Mednax worth $11,595,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Bremer Trust National Association increased its position in Mednax by 0.6% in the third quarter. Bremer Trust National Association now owns 5,025 shares of the company’s stock valued at $333,000 after buying an additional 30 shares in the last quarter. Profund Advisors LLC increased its position in Mednax by 0.3% in the second quarter. Profund Advisors LLC now owns 12,470 shares of the company’s stock valued at $903,000 after buying an additional 35 shares in the last quarter. Montag & Caldwell LLC increased its position in Mednax by 0.5% in the second quarter. Montag & Caldwell LLC now owns 12,900 shares of the company’s stock valued at $934,000 after buying an additional 60 shares in the last quarter. Utah Retirement Systems increased its position in Mednax by 0.6% in the second quarter. Utah Retirement Systems now owns 16,800 shares of the company’s stock valued at $1,217,000 after buying an additional 100 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in Mednax by 1.4% in the second quarter. Mackenzie Financial Corp now owns 9,091 shares of the company’s stock valued at $658,000 after buying an additional 123 shares in the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Shares of Mednax Inc. (NYSE:MD) traded down 0.61% during trading on Monday, hitting $65.42. The company had a trading volume of 222,098 shares. The firm has a market capitalization of $6.06 billion, a P/E ratio of 17.97 and a beta of 0.62. Mednax Inc. has a 1-year low of $59.36 and a 1-year high of $76.96. The company’s 50 day moving average is $63.98 and its 200 day moving average is $67.41.

Mednax (NYSE:MD) last announced its quarterly earnings data on Thursday, October 27th. The company reported $1.09 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.11 by $0.02. The firm had revenue of $828 million for the quarter, compared to analysts’ expectations of $821.18 million. Mednax had a net margin of 10.97% and a return on equity of 14.47%. The business’s quarterly revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.10 earnings per share. Analysts anticipate that Mednax Inc. will post $4.04 earnings per share for the current fiscal year.

Several brokerages recently commented on MD. Citigroup Inc. reduced their target price on Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 17th. Raymond James Financial Inc. cut Mednax from an “outperform” rating to a “market perform” rating in a report on Thursday, October 27th. Zacks Investment Research cut Mednax from a “hold” rating to a “sell” rating in a report on Wednesday, September 28th. Mizuho reduced their target price on Mednax from $79.00 to $69.00 and set a “buy” rating on the stock in a report on Friday, October 28th. Finally, Jefferies Group reduced their target price on Mednax from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, August 26th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $74.44.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,500 shares of Mednax stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total value of $97,515.00. Following the transaction, the director now directly owns 12,755 shares of the company’s stock, valued at approximately $829,202.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by company insiders.

About Mednax

Related posts

Leave a Comment